Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review

被引：22

作者：

Alam, Naveed

Darling, Gail

Evans, William K.

Mackay, Jean A.

Shepherd, Frances A. ^{[1
]}

机构：

[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada

[5] McMaster Univ, Canc Care Ontario Program Evidence Based Care, Downtown Ctr, Hamilton, ON L8S 4L8, Canada

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 58卷 / 02期

关键词：

adjuvant treatment; chemotherapy; non-small cell lung cancer;

D O I：

10.1016/j.critrevonc.2005.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. Methods: Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. Results: Seven meta-analyses and 26 randomized trials comparing surgery with or without chemotherapy met the pre-defined eligibility criteria for the review. The meta-analyses all showed a survival advantage for platinum- or UFT-based postoperative chemotherapy, although the results did not always achieve statistical significance. The results of individual trials were inconsistent, although recent trials have detected a large survival advantage with postoperative platinum-based chemotherapy. Differences in trial design, patient characteristics, disease stage, use of radiotherapy and chemotherapy regimen may explain the variation in results. Conclusions: Postoperative adjuvant platinum-based chemotherapy improves survival compared with surgery alone in completely resected non-small cell lung cancer. In patients fit for chemotherapy, the survival benefits strongly outweigh the adverse effects of the treatment. (c) 2005 Cancer Care Ontario. Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：146 / 155

页数：10

共 51 条

[1] Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer - An analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature [J].

Alam, N ;

Shepherd, FA ;

Winton, T ;

Graham, B ;

Johnson, D ;

Livingston, R ;

Rigas, J ;

Whitehead, M ;

Ding, K ;

Seymour, L .

LUNG CANCER, 2005, 47 (03) :385-394

[2]

ALBERTI W, 1995, BRIT MED J, V311, P899

[3] Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature [J].

Berghmans, T ;

Paesmans, M ;

Meert, AP ;

Mascaux, C ;

Lothaire, P ;

Lafitte, JJ ;

Sculier, JP .

LUNG CANCER, 2005, 49 (01) :13-23

[4]

BRIA E, 2005, ASCO ORG VIRT M

[5]

Bria E., 2005, J CLIN ONCOL, V23, pA7140

[6]

BRIA E, 2004, ANN ONCOL, V15, pA646

[7] THE PRACTICE GUIDELINES DEVELOPMENT CYCLE - A CONCEPTUAL TOOL FOR PRACTICE GUIDELINES DEVELOPMENT AND IMPLEMENTATION [J].

BROWMAN, GP ;

LEVINE, MN ;

MOHIDE, EA ;

HAYWARD, RSA ;

PRITCHARD, KI ;

GAFNI, A ;

LAUPACIS, A .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :502-512

[8]

Burdett S, 1998, LANCET, V352, P257

[9]

DAUTZENBERG B, 1995, CANCER, V76, P779, DOI 10.1002/1097-0142(19950901)76:5<779::AID-CNCR2820760511>3.0.CO

[10]

2-O

← 1 2 3 4 5 6 →